Abbott Laboratories (ABT)
Pre-market:
| Previous close | 109.25 |
| Open | 109.79 |
| Bid | 108.43 x 900 |
| Ask | 0.00 x 1300 |
| Day's range | 108.59 - 109.98 |
| 52-week range | 101.24 - 142.60 |
| Volume | |
| Avg. volume | 5,134,569 |
| Market cap | 190.883B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 22.76 |
| EPS (TTM) | 4.79 |
| Earnings date | 18 Oct 2022 - 24 Oct 2022 |
| Forward dividend & yield | 1.88 (1.72%) |
| Ex-dividend date | 14 July 2022 |
| 1y target est | 127.91 |
- Editor's pickYahoo Finance
Big Tech off the hook; Abbott under fire; Musk-Twitter feud: 3 legal stories to watch
This week, in legal news Yahoo Finance is following stalled legislation that would have reined in Big Tech; lawsuits piling up against formula maker Abbott; and a simmering legal feud between Twitter and Tesla CEO Elon Musk.
- Motley Fool
Should You Really Care About This Company's Short-Term Success?
Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
- PR Newswire
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers' diabetes-tailored weight management program with Abbott's portfolio of FreeStyle Libre® products to create a seamless mobile experience that will give people living with diabetes the information and insights needed to make h
